VERAXA Biotech Completes Business Combination, Begins Trading on Nasdaq

VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp., resulting in the formation of VERAXA Biotech AG. The company will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. This milestone enables VERAXA to advance its proprietary BiTAC platform, which develops bispecific T-cell engagers and antibody-drug conjugates designed to selectively target cancer cells while sparing healthy tissue.

Proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support the advancement of VERAXA's BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate. For more details, the full press release is available at https://ibn.fm/ka00j.

VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. For regular updates, visit www.veraxa.com.

Voyager Acquisition Corp., the special purpose acquisition company that merged with VERAXA, has a mission to revolutionize the healthcare sector through mergers, stock purchases, or business combinations. The team includes experienced executives with expertise in investing, operations, and medical innovation. More information is available at https://www.voyageracq.com.

The business combination and associated financings position VERAXA to potentially bring novel cancer therapies to patients. The BiTAC platform's ability to selectively target cancer cells could offer advantages over traditional approaches, reducing side effects while enhancing efficacy. As the company transitions from preclinical to clinical development, investors and the medical community will be watching closely for data from upcoming trials.